aTyr Pharma, Inc. (ATYR) vs Pluri Inc. (PLUR)

aTyr Pharma, Inc. and Pluri Inc. are both Biotechnology companies. aTyr Pharma, Inc. and Pluri Inc. are of similar size ($15.0M and $14.8M). aTyr Pharma, Inc. grew revenue faster over the last twelve months: 6.78% against −24.0%. aTyr Pharma, Inc. has the higher net margin (0.00% vs −2,344.6%) and the higher return on invested capital (0.00% vs −526.9%). Across the 17 metrics below, aTyr Pharma, Inc. leads on 9 and Pluri Inc. on 8.

Valuation

Metric ATYR PLUR Biotechnology median
P/E n/m n/m 10.60
P/S 1.38 11.89 9.40
P/B 0.32 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.61 n/m 0.66
EV/Sales (3.49) 31.96 9.02
Earnings yield (397.17%) (197.58%) (32.88%)
Free cash flow yield (355.97%) (167.21%) (23.13%)

Profitability

Metric ATYR PLUR Biotechnology median
Gross margin 1.72% 44.59% 68.51%
Operating margin 0.00% (2,454.53%) 0.00%
Net margin 0.00% (2,344.59%) 0.00%
Free cash flow margin 0.00% (1,988.48%) 0.00%
Return on equity (98.67%) 260.35% (51.96%)
Return on assets (70.97%) (74.95%) (46.06%)
Return on invested capital 0.00% (526.92%) 0.00%

Growth

Metric ATYR PLUR Biotechnology median
Revenue growth (TTM) 6.78% (23.95%) 6.76%
EPS growth (last fiscal year) 7.54% 31.46% 29.88%
Revenue growth, 5-year CAGR (14.75%) 113.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATYR PLUR Biotechnology median
Debt to equity 0.00 (1.62) 0.00
Current ratio 5.12 0.27 4.97
Net debt to EBITDA 1.01 (0.83) 1.01

Dividend

Metric ATYR PLUR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ATYR PLUR Biotechnology median
Market cap 14.78m 15.00m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack